Checkpoint Blockade Immunotherapy

Checkpoint blockade immunotherapy is an innovative treatment that uses medications known as immune checkpoint inhibitors to address several types of cancer. Specifically, these medications can help the body’s immune system recognize and attack cancerous cells.

Some types of cancer produce proteins that inhibit the natural response of the body's immune system. These proteins exploit the immune system's checkpoints, which are mechanisms that can differentiate between healthy and foreign cells and prevent the body from attacking healthy cells. By circumventing these checkpoints, cancerous cells can avoid detection and continue to spread. By blocking the interaction between the immune system and the cancer cell’s proteins, however, immune checkpoint therapy can effectively "release the brakes" on the immune system and help the body fight the cancer.

Checkpoint blockade immunotherapy has shown promise in treating a variety of malignancies, including:

  • Melanoma
  • Lung cancer
  • Kidney cancer
  • Bladder cancer
  • Hodgkin’s lymphoma
  • Ovarian cancer

Cellular immunotherapy is a very active area of research at Moffitt, and we continue to make great strides in increasing its effectiveness and expanding its use in cancer treatment. Our outstanding research program is widely acclaimed and has received national recognition in the form of a Comprehensive Cancer Center designation from the National Cancer Institute.

At Moffitt Cancer Center, our patients not only have access to checkpoint blockade immunotherapy and other advanced treatments, but also can benefit from our robust clinical trials program. Taking a multispecialty approach to cancer treatment, we can match patients with various clinical trials that are appropriate for their unique needs.

If you’d like more information about checkpoint blockade immunotherapy, contact Moffitt Cancer Center at 1-888-663-3488 or complete a new patient registration form online. You do not need a referral to participate in our clinical trials program.